On May 11, 2026, Evolus introduced Estyme to European markets, marking its first rollout outside North America for this performance beauty product. The launch complements its existing Jeuveau neurotoxin and Evolysse hyaluronic acid gel offerings, positioning the company to capture growing demand for aesthetic contouring solutions.

Three days later, on May 14, 2026, Evolus finalized its NUCEIVA safety study, fulfilling a critical requirement for its aesthetic toxin platform. The completion of this study reduces regulatory uncertainty and could accelerate submission timelines for broader approvals.

Following these developments, BTIG reaffirmed its Buy rating on Evolus, reflecting optimism about revenue growth from its diversified product mix. The combined impact of new product launches and lower regulatory risk supports a more robust commercial outlook for the rest of 2026.